In Reply We agree with Bavishi et al and Gąsowski et al that adverse events are an important consideration during antihypertensive treatment. However, while potential adverse effects of intensive systolic blood pressure (SBP) reduction should be considered carefully, to our knowledge, these effects have not yet been consistently proven in published clinical trials. Conversely, several published clinical trials and meta-analyses,1-3 including our network meta-analysis,2 which compared a wide range of achieved SBP levels, have documented important benefits of intensive SBP reduction below current treatment guidelines on cardiovascular disease (CVD) in patients with hypertension who are at high risk for CVD. Furthermore, these studies have demonstrated that intensive SBP reduction lowered all-cause mortality. Therefore, the benefits of intensive SBP reduction are of substantial clinical import and likely outweigh the potential adverse effects.
Bundy JD, Whelton PK, He J. Safety vs Efficacy of Lowering Blood Pressure—Reply. JAMA Cardiol. 2017;2(12):1399–1400. doi:10.1001/jamacardio.2017.3543
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: